key: cord-0838877-xyfrc1jp
authors: Haslwanter, Denise; Dieterle, M. Eugenia; Wec, Anna Z.; O’Brien, Cecilia M.; Sakharkar, Mrunal; Florez, Catalina; Tong, Karen; Rappazzo, C. Garrett; Lasso, Gorka; Vergnolle, Olivia; Wirchnianski, Ariel S.; Bortz, Robert H.; Laudermilch, Ethan; Fels, J. Maximilian; Mengotto, Amanda; Malonis, Ryan J.; Georgiev, George I.; Quiroz, Jose A.; Wrapp, Daniel; Wang, Nianshuang; Dye, Kathryn E.; Barnhill, Jason; Dye, John M.; McLellan, Jason S.; Daily, Johanna P.; Lai, Jonathan R.; Herbert, Andrew S.; Walker, Laura M.; Chandran, Kartik; Jangra, Rohit K.
title: A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
date: 2021-06-11
journal: bioRxiv
DOI: 10.1101/2021.06.10.447999
sha: 15ca208bb3e5109ef43c37a7273938daf720f1ea
doc_id: 838877
cord_uid: xyfrc1jp

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain (RBD) of the spike (S) protein. Variants of concern (VOC) carrying mutations in the RBD or other regions of S reduce the effectiveness of many nAbs and vaccines by evading neutralization. Therefore, therapies that are less susceptible to resistance are urgently needed. Here, we characterized the memory B-cell repertoire of COVID-19 convalescent donors and analyzed their RBD and non-RBD nAbs. We found that many of the non-RBD-targeting nAbs were specific to the N-terminal domain (NTD). Using neutralization assays with authentic SARS-CoV-2 and a recombinant vesicular stomatitis virus carrying SARS-CoV-2 S protein (rVSV-SARS2), we defined a panel of potent RBD and NTD nAbs. Next, we used a combination of neutralization-escape rVSV-SARS2 mutants and a yeast display library of RBD mutants to map their epitopes. The most potent RBD nAb competed with hACE2 binding and targeted an epitope that includes residue F490. The most potent NTD nAb epitope included Y145, K150 and W152. As seen with some of the natural VOC, the neutralization potencies of COVID-19 convalescent sera were reduced by 4-16-fold against rVSV-SARS2 bearing Y145D, K150E or W152R spike mutations. Moreover, we found that combining RBD and NTD nAbs modestly enhanced their neutralization potential. Notably, the same combination of RBD and NTD nAbs limited the development of neutralization-escape mutants in vitro, suggesting such a strategy may have higher efficacy and utility for mitigating the emergence of VOC. Importance The US FDA has issued emergency use authorizations (EUAs) for multiple investigational monoclonal antibody (mAb) therapies for the treatment of mild to moderate COVID-19. These mAb therapeutics are solely targeting the receptor binding domain of the SARS-CoV-2 spike protein. However, the N-terminal domain of the spike protein also carries crucial neutralizing epitopes. Here, we show that key mutations in the N-terminal domain can reduce the neutralizing capacity of convalescent COVID-19 sera. We report that a combination of two neutralizing antibodies targeting the receptor binding and N-terminal domains may have higher efficacy and is beneficial to combat the emergence of virus variants.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a member of the 67 family Coronaviridae, and the causative agent of the ongoing coronavirus disease 68 2019 (COVID-19) pandemic (1) . Over 171 million cases have been officially diagnosed 69 since its first emergence and >3.6 million people have succumbed to disease (2). 70 Public health measures, along with rapid vaccine development have helped slow the 71 pandemic in some countries. Moreover, small molecule inhibitors, antibody-based 72 therapeutics, and convalescent plasma from COVID-19 convalescents have received 73 emergency use authorizations (EUAs) (3). Recently, multiple virus variants of concern 74 (VOC), some carrying neutralizing antibody (nAb)-resistant mutations that are 75 associated with increased transmission and fatality rates, have emerged (4). The 76 availability of multiple therapeutic approaches especially for people who cannot get 77 vaccinated is essential. There is thus an urgent need to develop therapeutics, 78 especially ones that limit the emergence of neutralization-resistant variants or are 79 4 more efficient against them as they can help save lives while vaccines are being 80 deployed. 81 SARS-CoV-2 entry into host cells is mediated by the transmembrane spike (S) 82 glycoprotein, which forms trimeric spikes protruding from the viral surface (5). Each 83 monomer, 180-200 kDa in size, comprises S1 and S2 subunits that are generated by 84 post-translational cleavage by the host enzyme furin. The S1 subunit is composed of 85 two domains, an N-terminal domain (NTD) and a C-terminal domain (CTD). The CTD 86 functions as the receptor-binding domain (RBD) for the entry receptor, human 87 angiotensin-converting enzyme 2 (hACE2) (6, 7). The role of the NTD for SARS-CoV-88 2 is unclear, but it has been proposed in other coronaviruses to play roles in 89 recognizing specific sugar moieties during attachment and regulating the prefusion-to-90 postfusion transition of the S protein (8-10). The S2 subunit is composed of the fusion 91 peptide, heptad repeats 1 and 2, a transmembrane domain and a cytoplasmic tail. 92 Aided by hACE2-binding and host cathepsin-and/or transmembrane protease serine 93 2 (TMPRSS2)-mediated proteolytic processing, S2 undergoes extensive 94 conformational rearrangement to insert its fusion peptide into the host membrane and 95 mediate the fusion of host and viral membranes (6, 7). 96 The S protein is the major target of nAbs, the production of which is a key correlate of 97 protection following virus infection and vaccination (11) (12) (13) (14) . Due to their potential to 98 interfere with hACE2 interaction and to efficiently neutralize virus infection, RBD-99 specific antibodies have been the main focus of human monoclonal antibody (mAb)-100 based therapeutics (13, (15) (16) (17) (18) (19) (20) . We recently described the memory B-cell repertoire 101 of a convalescent SARS donor and isolated multiple RBD-specific antibodies that 102 neutralize and protect against SARS-CoV, SARS-CoV-2 and WIV1 viruses (19, 20) . 103 Since that time, multiple RBD-targeting mAbs have received emergency use 104 5 authorizations by the US FDA. However, the widespread circulation of nAb-resistant 105 variants has led to the withdrawal of EUAs for some nAb monotherapies (21) 106 highlighting the need to develop combination-nAb therapies that can treat SARS-CoV-107 2 variants and reduce the probability of mutational escape. In fact, a few of the VOC 108 carry mutations in some of the major neutralizing epitopes in the RBD as well as the 109 NTD (22). 110 Recently, multiple NTD mAbs with potent neutralizing activity have been described 111 (17, (23) (24) (25) (26) (27) (28) . As combinations of mAbs targeting distinct epitopes and mechanisms of 112 action have been successfully used against other viruses (29, 30), cocktails of RBD 113 and NTD mAbs have been proposed and recently showed promise against CoV-2 in vitro and in vivo (23, 24) . 115 To evaluate the effect of combining nAbs targeting the RBD and the NTD, here, we 116 mined the memory B-cell repertoires of four convalescent COVID-19 donors with high 117 serum neutralization and spike-specific antibody titers. By sorting spike-reactive single 118 B-cells, we isolated 163 mAbs targeting S. Further, we evaluated their neutralization 119 capacity against authentic SARS-CoV-2 and a self-replicating vesicular stomatitis 120 virus carrying SARS-CoV-2 S protein (rVSV-SARS2) (31). We downselected the top 121 RBD-and NTD-targeting neutralizers and used multiple approaches to map their 122 epitopes. As described recently (32, 33), we observed that neutralization-escape 123 rVSV-SARS2 mutants of the NTD-targeting mAb were resistant to neutralization by 124 COVID-19 convalescent donor sera, suggesting that natural variants in the NTD could, 125 at least in part, escape the antibody response. Here, we show that a combination of 126 the NTD-and RBD-targeting mAbs neutralized virus more efficiently and limited the 127 emergence of neutralization-escape spike mutants, underscoring the utility of 128 combination therapy. 

131 convalescent patients. 132 To characterize the B-cell responses induced by SARS-CoV-2 infection, we sampled 133 peripheral blood mononuclear cells (PBMCs) from four adult patients (EMC 5, 9, 10 134 and 15) at the Montefiore Medical Center in the Bronx (Einstein-Montefiore COVID-135 19). They were all previously healthy individuals who developed mild COVID-19. For each donor, we single-cell sorted SARS-CoV-2 S-reactive class-switched 142 (CD19 + IgM -IgD -) B-cells, which ranged in frequency between 0.6 and 1.2% across the 143 donors ( Fig. S1B-C) . Index-sorting analysis revealed that the S-specific B-cells were 144 predominantly IgG + , and the majority expressed the classical memory B-cell marker 145 CD27 (41-76%) (Fig. 1A) . Additionally, 44-67% expressed the activation/proliferation 146 marker CD71 (Fig. 1B) , consistent with the early time post-infection. Antibodies from 147 all four donors showed similar levels of somatic hypermutation, as evidenced by the 148 median number of nucleotide substitutions in the heavy-chain variable region that are 149 consistent with the early time point post infection (range 1-3) (Fig. 1C) . Although VH 150 germline genes such as VH3-30 and VH3-30-3 were over-represented in all individuals 151 as has been seen previously (27), less than 5% of clones were derived from clonally 152 expanded lineages (Fig. 1D-E) . Altogether, these results indicate a robust and diverse 

From the cloned pairs of VH and VL genes of the four donors, we expressed and 178 purified mAbs in a human IgG1 background using our yeast expression platform. 179 These mAbs were screened for their S protein binding ability and the top 163 mAbs 180 binders were evaluated for their neutralizing activity against authentic SARS-CoV-2 181 and rVSV-SARS2 at 100 nM and 10 nM antibody concentrations in micro-182 neutralization assays, respectively. A total of 44 mAbs neutralized authentic virus with 183 more than 50% efficacy and 34 mAbs did the same for rVSV-SARS2 ( Fig. 2A) . Based 184 on these data, we selected the top 40 nAbs for further analyses and used biolayer 185 interferometry (BLI) to identify the specific domains of the S protein targeted by these 186 nAbs. Most of the nAbs mapped to the RBD and included hACE2 competitors and 187 non-competitors. However, we also identified multiple non-RBD binding nAbs 188 including many that target the NTD (Fig. 2B) . Finally, we ran 9-point neutralization 189 curves on all 40 nAbs with authentic virus and rVSV-SARS2 to down-select to four 190 each of the most potent RBD-and non-RBD targeting antibodies (data not shown). 191 The neutralizing profiles of the RBD-targeting mAbs against rVSV-SARS2 and the 192 authentic SARS-CoV-2 were very similar, with IC50 neutralization values in the 193 picomolar range for ADI-56443 (75 pM) and ADI-56899 (89 pM) (Fig. 2C) . As has 194 been observed previously for NTD-targeting mAbs (25) , rVSV-SARS2 neutralization 195 curves for the non-RBD mAbs were shallower and these mAbs left an un-neutralized 196 fraction of the virus (Fig. 2D, right panel) . However, there was no un-neutralized the NTD mutations generated in response to the ADI-56479 mAb-driven selection 274 (Fig. 4) . Using a set of convalescent sera with high neutralizing activity (reciprocal 275 serum neutralization IC50 titers of >500), we observed a significant effect of NTD point 276 mutations on rVSV-SARS2 neutralization (Fig. 4A) . Specifically, the sera showed a 277 drop of 3.5-fold (Y145D) to 16-fold (K150E and W152R) in their neutralization IC50 278 titers as compared to the parental virus (Fig. 4B) . Thus, our data further supports a 279 significant role of the NTD-targeting antibodies in polyclonal sera-mediated SARS- Combination of RBD and NTD monoclonal antibodies limit the generation of 295 neutralization-escape mutants. 296 Since the top RBD (ADI-46443) and NTD (ADI-56479) nAbs bind to two distinct 297 domains of the S protein (Fig. 3D) , we reasoned that combining them may enhance 298 their neutralization efficacy. Given the vastly different IC50 values of the two mAbs with 299 rVSV-SARS2, we were not able to calculate a classical synergy combination index 300 (CI) analysis based on their equimolar combination at IC50 (42). However, we did 301 observe a modest left shift in the rVSV-SARS2 neutralization curve by combining each 302 mAb starting at their IC90 concentrations (Fig. 5A) . Next, we evaluated if combining 303 the two mAbs, in 1:1 ratio at their neutralization IC90 concentrations, also has an effect 304 on limiting the emergence of rVSV-SARS2 neutralization-escape mutants as 305 compared to the single mAbs (Fig. 5B) . As expected, rVSV-SARS2 rather easily 306 escaped individual mAbs reaching a peak titer of 3x10 6 (RBD nAb) and 2.7x10 5 (NTD 13, [15] [16] [17] [18] 20) . However, potent non-RBD nAbs are 327 present in COVID-19-convalescent patients, and the emergence of NTD mutations 328 that afford resistance to neutralization in multiple SARS-CoV-2 VOC highlights the 329 importance of NTD as an important target for nAbs. Here, we isolated potent RBD and 330 NTD nAbs from multiple COVID-19 donors and mapped their epitopes in the S protein. 331 We show that neutralization-escape mutations to the NTD nAb significantly reduce the 332 efficacy of polyclonal COVID-19 convalescent sera. Importantly, a combination of RBD 333 and NTD mAbs modestly increased efficacy and could effectively limit the emergence 334 of nAb-resistant S mutations. 335 Consistent with the increasingly recognized importance and prevalence of non-RBD 336 nAbs (41), 12 of our top 40 nAbs targeted NTD ( Fig. 1 and 2) . Six of these NTD nAbs 337 were derived from two variable heavy (VH) genes (VH1-24 or VH3-30), suggesting 338 their preponderance in NTD nAbs. Some NTD nAbs require significant somatic 339 hypermutations for their efficacy (23, 27). However, 11 out of the 12 nAbs that we 340 discovered carried ≤3 somatic hypermutations, indicating that they arose at an early (43). Here, we show that a potent NTD nAb (ADI-56479) interacts with 351 residues Y145, K150 and W152 in the NTD (Fig. 3) , which are located in the N3 loop 352 of an 'antigenic supersite.' Other potent NTD nAbs also recognize the same antigenic 353 supersite (17, (23) (24) (25) 27) . Recently, Suryadevara et al. (24) showed that mutations 354 F140S, and G142D or R158S in the NTD confer resistance of two other NTD nAbs. 355 Notably, our rVSV-SARS2 neutralization-escape variants (Y145D, K150E and 356 W152R) were significantly resistant to neutralization by convalescent COVID-19 sera 357 (Fig. 4) . In addition, mutations at N148S, K150R/E and S151P in the NTD epitope 358 exhibited reductions in sensitivity to three COVID-19 convalescent plasma samples 359 (32). A deletion at F140 that occurred in response to immune pressure from highly 360 neutralizing convalescent plasma also partially reduced neutralization (33). 466 Prefusion-stabilized SARS-CoV-2 S-2P spike ectodomain (residues 1-1208) was 467 expressed and purified as described previously (7) to achieve a sensor response between 1-1.4 nm followed by an inert IgG to occupy 532 any remaining binding sites on the biosensor. The sensors were then equilibrated for 533 a minimum of 30 min. The loaded sensors were additionally exposed to hACE2 for 90 534 secs, prior to the binning analysis to assess any interactions between secondary 535 molecules and proteins on the sensor surface. After a 60-seconds baseline step, 536 association to recombinant SARS-CoV-2 RBD was performed for 180 secs and was 537 finally followed by exposure to hACE2. The data was analyzed using the ForteBio Data 538 Analysis Software version 11.0. The absence of binding by the secondary molecule 539 28 indicates an occupied epitope (competitor) and binding indicates a non-competing 540 antibody.

Epitope mapping using a yeast-display library 542 Epitope mapping was done using a library of SARS-CoV-2 RBD point mutants 543 displayed on the yeast surface as described previously (47) and evaluated for their binding to ADI-56643 at EC80 concentration by flow cytometry. 553 Binding signal was normalized to that of the reference WT RBD-SD1 (set as 100%).

Generation of rVSV-SARS2 that escaped neutralization with our top RBD (ADI-56443) 556 and NTD (ADI-56479) mAbs was done as described previously (19). Briefly, rVSV-557 SARS2 was pre-incubated with IC90 concentrations of ADI-56443 (0.37 nM) and ADI-558 56479 (100 nM) were applied to monolayers of Vero cells and infection was allowed 559 to proceed in the presence of the mAbs. Virus supernatants were harvested from the 560 cells at 48-72 hpi and passaged again by doubling the amount of antibody for 561 subsequent passage. After 3 passages, mAb-resistant viruses were plaque-purified, 562 their phenotypes were confirmed by neutralization assay and S gene sequences were 563 determined by RT-PCR followed by Sanger sequencing as described previously (31). 

A new coronavirus associated with human 610 respiratory disease in China

An interactive web-based dashboard to track 612 COVID-19 in real time

Drug treatments for covid-19: living systematic review and 617 network meta-analysis

Risk of mortality in patients infected with SARS-CoV-2 variant 620 of concern 202012/1: matched cohort study

Structure, function, and evolution of coronavirus spike proteins

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the 628 prefusion conformation

Point mutations in the S 630 32 protein connect the sialic acid binding activity with the enteropathogenicity of 631 transmissible gastroenteritis coronavirus

Structural and functional analysis of the surface 633 protein of human coronavirus OC43

Bat-to-human: spike features determining "host 635 jump" of coronaviruses SARS-CoV, MERS-CoV, and beyond

Structures of Human Antibodies 641 Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent 642 Features of Antibodies

Kyratsous 646 CA. 2020. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in 647 rhesus macaques and hamsters

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 652 antibody cocktail

A SARS-CoV-2 Infection Model in Mice Demonstrates 657 Protection by Neutralizing Antibodies

Xie 660 XS. 2020. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by

Human neutralizing antibodies elicited by SARS-CoV-2 666 infection

Potent neutralizing 670 antibodies against multiple epitopes on SARS-CoV-2 spike

Corti 675 D. 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-676

CoV antibody

Broad neutralization of SARS-related viruses by human monoclonal 681 antibodies

Crowe 685 JE. 2020. Rapid isolation and profiling of a diverse panel of human monoclonal 686 antibodies targeting the SARS-CoV-2 spike protein

Authorization for Monoclonal Antibody Bamlanivimab | FDA. FDA NEWS 689 RELEASE

SARS-CoV-2 Variant Classifications and Definitions

N-terminal domain antigenic mapping reveals a site of 695 vulnerability for SARS-CoV-2

Neutralizing and protective human monoclonal antibodies recognizing 700 the N-terminal domain of the SARS-CoV-2 spike protein

A neutralizing human antibody binds to the N-terminal 705 domain of the Spike protein of SARS-CoV-2

Huang 708 Z, Cong Y. 2021. Conformational dynamics of SARS-CoV-2 trimeric spike 709 glycoprotein in complex with receptor ACE2 revealed by cryo-EM

Potent SARS-CoV-2 713 neutralizing antibodies directed against spike N-terminal domain target a single 714 supersite

Structure-based 717 development of human antibody cocktails against SARS-CoV-2

Development of a Human Antibody Cocktail that Deploys Multiple 723

Functions to Confer Pan-Ebolavirus Protection

A Two-Antibody Pan-Ebolavirus Cocktail Confers 728

Broad Therapeutic Protection in Ferrets and Nonhuman Primates

A Replication-Competent Vesicular Stomatitis Virus for 734 Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition

Escape from neutralizing antibodies by 740 SARS-CoV-2 spike protein variants

CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent 745 plasma

Prolonged evolution of the human B cell response 749 to SARS-CoV-2 infection

Evolution of antibody immunity to SARS-CoV-2. 754

Rapid 757 generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid 758 proteins in COVID-19 and convalescence

Commonality despite 760 exceptional diversity in the baseline human antibody repertoire

The neutralizing antibody

CoV555, protects against SARS-CoV-2 infection in nonhuman primates

FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY 771 USE AUTHORIZATION (EUA) OF REGEN-COVTM (casirivimab with 772 imdevimab)

Prevalent, protective, and convergent IgG recognition of 777 SARS-CoV-2 non-RBD spike epitopes

Quantitative analysis of dose-effect relationships: 780 the combined effects of multiple drugs or enzyme inhibitors

Structural definition of a neutralization epitope 784 on the N-terminal domain of MERS-CoV spike glycoprotein

antibody neutralization of an emerging SARS-CoV-2 variant in 791 California carrying a L452R spike protein mutation

CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR

Transformation of yeast by lithium 796

acetate/single-stranded carrier DNA/polyethylene glycol method

Broad and potent activity against SARS-like 802 viruses by an engineered human monoclonal antibody